➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
Express Scripts
Johnson and Johnson
Colorcon

Last Updated: January 22, 2021

DrugPatentWatch Database Preview

Covis Pharma Bv Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for COVIS PHARMA BV, and when can generic versions of COVIS PHARMA BV drugs launch?

COVIS PHARMA BV has twelve approved drugs.

There are three US patents protecting COVIS PHARMA BV drugs.

There are ninety-seven patent family members on COVIS PHARMA BV drugs in thirty-six countries and five supplementary protection certificates in two countries.

Summary for Covis Pharma Bv
International Patents:97
US Patents:3
Tradenames:12
Ingredients:8
NDAs:12

Drugs and US Patents for Covis Pharma Bv

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 DISCN Yes No   Start Trial   Start Trial
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-005 Mar 14, 2003 DISCN No No   Start Trial   Start Trial
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-006 Apr 2, 2003 DISCN No No   Start Trial   Start Trial
Covis Pharma Bv BETAPACE AF sotalol hydrochloride TABLET;ORAL 021151-002 Feb 22, 2000 AB RX Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Covis Pharma Bv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-006 Jan 2, 2008 5,626,874   Start Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 4,703,038   Start Trial
Covis Pharma Bv OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 6,939,559   Start Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-005 Jan 2, 2008 5,422,123   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for COVIS PHARMA BV drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2012-02-13
➤ Subscribe Extended-release Tablets 25.5 mg and 34 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 8.5 mg and 17 mg ➤ Subscribe 2009-03-02
➤ Subscribe Capsules 2 mg, 4 mg and 6 mg ➤ Subscribe 2007-08-10
➤ Subscribe Extended-release Tablets 20 mg and 30 mg ➤ Subscribe 2007-11-07
➤ Subscribe Extended-release Tablets 40 mg ➤ Subscribe 2007-06-11

Supplementary Protection Certificates for Covis Pharma Bv Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 2012/048 Ireland   Start Trial PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1411900 SPC/GB11/015 United Kingdom   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957 SPC/GB11/013 United Kingdom   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0124495 SPC/GB01/006 United Kingdom   Start Trial PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Johnson and Johnson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.